Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Joy Schrader

Nurse Practitioner Mason City, IA Nurse Practitioner

NPI 1467601062 CMS profile 10852659

910 N Eisenhower Ave, Mason City, IA 50401

Open in the dashboard

General payments

$1,670

34 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Joy Schrader of Mason City, IA is reported in the CMS Open Payments database as having received $1,670 across 34 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,296 18
2024 General $69 4
2023 General $109 5
2022 General $85 2
2021 General $111 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joy Schrader
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Joy Schrader were reported at $1,296. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Joy Schrader Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $111 $135 $40–$426 $132
2022 $85 $152 $48–$470 $149
2023 $109 $166 $54–$529 $160
2024 $69 $173 $55–$556 $164
2025 $1,296 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Medtronic, Inc. $1,112 15 payments
  2. Novo Nordisk Inc $253 4 payments
  3. Abbott Laboratories $130 5 payments
  4. Insulet Corporation $76 3 payments
  5. Biohaven Pharmaceuticals, Inc. $51 4 payments
  6. Dexcom, Inc. $35 2 payments
  7. Tandem Diabetes Care, Inc. $13 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $906 27 payments
  2. Travel and Lodging $764 7 payments
Products named General payments · program years 2021–2025
  1. MINIMED 780G $1,112 15 payments
  2. Ozempic $193 3 payments
  3. FreeStyle Libre 3 $82 3 payments
  4. Omnipod $76 3 payments
  5. RYBELSUS $60 1 payment
  6. NURTEC ODT $51 4 payments
  7. FreeStyle Libre 2 $49 2 payments
  8. Dexcom G6 Transmitter $35 2 payments
  9. t:slim X2 Insulin Pump with Control-IQ $13 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 56 drugs

Part D claims

5,198

Median for Nurse Practitioner: 389

Drug cost

$3,108,882

Median for Nurse Practitioner: $21,885

Branded share of claims

91.7%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 711 $917,924
Jardiance Empagliflozin Brand 598 $518,351
Trulicity Dulaglutide Brand 256 $287,599
Farxiga Dapagliflozin Propanediol Brand 229 $190,654
Mounjaro Tirzepatide Brand 154 $169,945
Soliqua 100-33 Insulin Glargine/Lixisenatide Brand 159 $169,636
Tresiba Flextouch U-200 Insulin Degludec Brand 103 $93,709
Rybelsus Semaglutide Brand 62 $85,588
Fiasp Flextouch Insulin Aspart (Niacinamide) Brand 83 $63,530
Novolog Flexpen Insulin Aspart Brand 205 $57,675

The 10 drugs with the highest cost, of 56 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$61,282

Medicare's payments for the services billed

Medicare patients

335

Average age 73

Services billed

1,912

174 women, 161 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Diabetes 75%
High blood pressure 75%
Arthritis 43%
Chronic kidney disease 41%
Ischemic heart disease 37%
Heart failure 31%
Depression 28%
Atrial fibrillation 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

34 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Iowa

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record